CooperCompanies | | | | FY26 Guidance | Q1 2026 Guidance | | --- | --- | --- | --- | --- | | | Total | $4,299 - | $4,338 | $1,019 - $1,030 | | | | (4.5% - | 5.5% organic growth) | (3% - 4% organic growth) | | e | | | | | | u n e | CooperVision | $2,900 - | $2,925 | $693 - $700 | | v | | (4.5% - | 5.5% organic growth) | (3.5% - 4.5% organic growth) | | e R | | | | | | | CooperSurgical | $1,399 - | $1,413 | $327 - $330 | | | | (4% - | 5% organic growth) | (2% - 3% organic growth) | | P | | | | | | A A | EPS | ...

Group 1 - The Cooper Companies Inc is a specialty medical device company with two business segments: CooperVision and CooperSurgical [11] - COO has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a solid position in the market [11][12] - The company has a Value Style Score of B, supported by a forward P/E ratio of 16.33, making it attractive for value investors [11][12] Group 2 - Five analysts have revised their earnings estimates higher for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.02 to $4.08 per share [12] - COO has an average earnings surprise of +2.5%, suggesting a positive trend in earnings performance [12]